<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04526509</url>
  </required_header>
  <id_info>
    <org_study_id>209012</org_study_id>
    <nct_id>NCT04526509</nct_id>
  </id_info>
  <brief_title>Master Protocol to Assess the Safety and Dose of First Time in Human Next Generation Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Advanced Solid Tumors</brief_title>
  <official_title>Master Protocol to Assess the Safety and Recommended Phase 2 Dose of Next Generations of Autologous Enhanced NY-ESO-1/ LAGE-1a TCR Engineered T-cells, Alone or in Combination With Other Agents, in Participants With Advanced Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial will evaluate the safety and efficacy of first time in human engineered T-cell&#xD;
      therapies, in participants with advanced tumors.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      New York esophageal antigen-1 (NY-ESO-1) and LAGE-1a antigens are tumor-associated proteins&#xD;
      that have been found in several tumor types. Clinical trials using adoptively transferred&#xD;
      T-cells directed against NY-ESO-1 have shown objective responses. GSK3901961 and GSK3845097&#xD;
      are next generation engineered T-cell receptor (TCR) T-cells, co-expressing the CD8Î± cell&#xD;
      surface receptor, targeting NY-ESO-1, and co-expressing the dnTGF-beta RII cell surface&#xD;
      receptor, targeting NY-ESO-1, respectively to potentially improve function. This is a master&#xD;
      protocol evaluating first time in human T-cell therapies. It will initially consist of two&#xD;
      independent substudies, investigating GSK3901961 and GSK3845097 in HLA-A*02+ participants&#xD;
      with NYESO1+ previously treated advanced (metastatic or unresectable) synovial sarcoma (SS)&#xD;
      and/or previously treated metastatic non-small cell lung cancer (NSCLC).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 21, 2020</start_date>
  <completion_date type="Anticipated">February 12, 2024</completion_date>
  <primary_completion_date type="Anticipated">February 12, 2024</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>This will be an open-label study. Hence, there will be no masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Substudy 1 and 2: Frequency of dose limiting toxicities (DLTs) according to severity.</measure>
    <time_frame>Until disease progression (up to 4 years)</time_frame>
    <description>Toxicities will be considered DLTs if they are considered at least possibly related to transduced T-cells; and they occur within the DLT-assessment period. Severity will be summarized using National Cancer Institute-Common Toxicity Criteria for Adverse Events (NCI-CTCAE), version (v) 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Substudy 1 and 2:Frequency of adverse events (AEs), serious adverse events (SAEs) and AEs of special interest (AESI) according to severity</measure>
    <time_frame>Until disease progression (up to 4 years)</time_frame>
    <description>AEs, SAEs and AESIs will be collected. Severity of AEs and SAEs will be summarized using NCI-CTCAE, version 5.0.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Substudy 1 and 2: Overall response rate (ORR)</measure>
    <time_frame>Until disease progression (up to 4 years)</time_frame>
    <description>Overall response rate is defined as the percentage of participants with a confirmed complete response (CR) or a confirmed partial response (PR) relative to the total number of participants within the analysis population at any time per Response evaluation criteria in solid tumors (RECIST) version 1.1 as determined by the local investigators.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 1 and 2: Duration of response (DOR)</measure>
    <time_frame>Until disease progression (up to 4 years)</time_frame>
    <description>Duration of response is defined as, in the subset of participants who show a confirmed CR or PR as assessed by local investigators, the time from first documented evidence of CR or PR until the first documented sign of disease progression or death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 1 and 2: Maximum expansion/persistence (Cmax)</measure>
    <time_frame>Until disease progression (up to 4 years)</time_frame>
    <description>Whole blood samples will be collected at indicated time points for evaluation of Cmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 1 and 2: Time to Cmax (Tmax)</measure>
    <time_frame>Until disease progression (up to 4 years)</time_frame>
    <description>Whole blood samples will be collected at indicated time points for evaluation of Tmax.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Substudy 1 and 2: Area under the concentration/persistence time curve from zero to time t (AUC[0-t])</measure>
    <time_frame>Until disease progression (up to 4 years)</time_frame>
    <description>Whole blood samples will be collected at indicated time points for evaluation of AUC (0 to t).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Neoplasms</condition>
  <arm_group>
    <arm_group_label>Substudy 1: GSK3901961 in previously treated advanced SS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as a single intravenous (IV) infusion after completing lymphodepleting chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 1: GSK3901961 in previously treated metastatic NSCLC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3901961, as a single IV infusion after completing lymphodepleting chemotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Substudy 2: GSK3845097 in previously treated advanced SS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eligible participants will be leukapheresed to manufacture engineered T-cells. Participants will then receive GSK3845097, as a single IV infusion after completing lymphodepleting chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3901961</intervention_name>
    <description>GSK3901961 as an IV infusion.</description>
    <arm_group_label>Substudy 1: GSK3901961 in previously treated advanced SS</arm_group_label>
    <arm_group_label>Substudy 1: GSK3901961 in previously treated metastatic NSCLC</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK3845097</intervention_name>
    <description>GSK3845097 as an IV infusion.</description>
    <arm_group_label>Substudy 2: GSK3845097 in previously treated advanced SS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.</description>
    <arm_group_label>Substudy 1: GSK3901961 in previously treated advanced SS</arm_group_label>
    <arm_group_label>Substudy 1: GSK3901961 in previously treated metastatic NSCLC</arm_group_label>
    <arm_group_label>Substudy 2: GSK3845097 in previously treated advanced SS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.</description>
    <arm_group_label>Substudy 1: GSK3901961 in previously treated advanced SS</arm_group_label>
    <arm_group_label>Substudy 1: GSK3901961 in previously treated metastatic NSCLC</arm_group_label>
    <arm_group_label>Substudy 2: GSK3845097 in previously treated advanced SS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Eligibility Criteria:&#xD;
&#xD;
        Inclusion criteria:&#xD;
&#xD;
          -  Participant must be &gt;=18 years of age on the day of signing informed consent.&#xD;
&#xD;
          -  Participant must be positive for Human leukocyte antigen (HLA)-A*02:01, HLA-A*02:05,&#xD;
             and/or HLA-A*02:06 alleles.&#xD;
&#xD;
          -  Participant's tumor is positive for NY-ESO-1 expression by a designated central&#xD;
             laboratory.&#xD;
&#xD;
          -  Performance status: Eastern Cooperative Oncology Group of 0-1.&#xD;
&#xD;
          -  Participant must have adequate organ function and blood cell counts 7 days prior to&#xD;
             leukapheresis.&#xD;
&#xD;
          -  Participant must have measurable disease according to RECIST v1.1.&#xD;
&#xD;
        Additional criteria for participants with synovial sarcoma:&#xD;
&#xD;
          -  Participant has advanced (metastatic or unresectable) synovial sarcoma confirmed by&#xD;
             histology.&#xD;
&#xD;
          -  Participant has received/completed treatment with anthracycline or with ifosfamide if&#xD;
             intolerant to anthracycline for advanced (metastatic or unresectable) disease and&#xD;
             progressed.&#xD;
&#xD;
        Additional criteria for participants with non-small cell lung cancer (NSCLC):&#xD;
&#xD;
          -  Participant has Stage IV NSCLC as confirmed by histology or cytology.&#xD;
&#xD;
          -  Participant has been previously treated with or is intolerant to programmed death&#xD;
             receptor-1 (PD)-1/Programmed death ligand 1 (PD-L1) checkpoint blockade therapy and a&#xD;
             platinum-based chemotherapy. For NSCLC that harbors an actionable genetic aberration&#xD;
             (e.g. BRAF, anaplastic lymphoma kinase [ALK]/ c-ros oncogene 1 [ROS1], etc ) per&#xD;
             National Comprehensive Cancer Network (NCCN) guidelines, participant has also been&#xD;
             previously treated with or is intolerant to the standard of care targeted therapy as&#xD;
             recommended by NCCN or equivalent country-level guidelines (e.g. European Society for&#xD;
             Medical Oncology [ESMO], National Institute for Health &amp; Care Excellence [NICE],&#xD;
             etc.).&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Central nervous system metastases, except in rare cases of NSCLC as specified in the&#xD;
             protocol.&#xD;
&#xD;
          -  Any other prior malignancy that is not in complete remission.&#xD;
&#xD;
          -  Clinically significant systemic illness.&#xD;
&#xD;
          -  Prior or active demyelinating disease.&#xD;
&#xD;
          -  History of chronic or recurrent (within the last year prior to leukapheresis) severe&#xD;
             autoimmune or immune mediated disease requiring steroids or other immunosuppressive&#xD;
             treatments.&#xD;
&#xD;
          -  Previous treatment with genetically engineered NY-ESO-1-specific T cells.&#xD;
&#xD;
          -  Previous NY-ESO-1 vaccine or NY-ESO-1 targeting antibody.&#xD;
&#xD;
          -  Prior gene therapy using an integrating vector.&#xD;
&#xD;
          -  Previous allogeneic hematopoietic stem cell transplant.&#xD;
&#xD;
          -  Washout periods for prior radiotherapy and systemic chemotherapy must be followed.&#xD;
&#xD;
          -  Major surgery &lt;=28 days of first dose of study intervention.&#xD;
&#xD;
          -  Pregnant or breastfeeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US GSK Clinical Trials Call Center</last_name>
    <phone>877-379-3718</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>EU GSK Clinical Trials Call Center</last_name>
    <phone>+44 (0) 20 89904466</phone>
    <email>GSKClinicalSupportHD@gsk.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Melinda Yushak</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westwood</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Benjamin Powers</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Reema Anil Patel</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Ladle</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Brian Van Tine</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Adam Schoenfeld</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Dejka Araujo</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jayesh Desai</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 2M4</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jonathan Noujaim</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-171 64</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>US GSK Clinical Trials Call Center</last_name>
      <phone>877-379-3718</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact>
    <contact_backup>
      <last_name>EU GSK Clinical Trials Call Centre</last_name>
      <phone>+44 (0) 20 8990 4466</phone>
      <email>GSKClinicalSupportHD@gsk.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jeffrey Yachnin</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Sweden</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 21, 2020</study_first_submitted>
  <study_first_submitted_qc>August 21, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 25, 2020</study_first_posted>
  <last_update_submitted>September 20, 2021</last_update_submitted>
  <last_update_submitted_qc>September 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adoptive T-cell therapy</keyword>
  <keyword>Advanced synovial sarcoma</keyword>
  <keyword>Advanced non-small cell lung cancer</keyword>
  <keyword>Advanced tumors</keyword>
  <keyword>GSK3845097</keyword>
  <keyword>GSK3901961</keyword>
  <keyword>T cell receptors</keyword>
  <keyword>Leukapheresis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>IPD for this study will be made available via the Clinical Study Data Request site.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study</ipd_time_frame>
    <ipd_access_criteria>Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.</ipd_access_criteria>
    <ipd_url>http://clinicalstudydatarequest.com</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

